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The dystonias are a relatively rare group of movement
disorders that often prove difficult to treat effectively. In
recent years, advances in our understanding of genetics has
allowed identification of a number of causative mutations,
as well as acquired aetiologies including peri-natal insults.
However, despite this progress, pharmacological treatment
options have remained limited and patients may still
acquire considerable disability as a consequence of the
disease. In contrast, the use of deep brain stimulation
(DBS), available since the late 1980s, has become more
widespread and now has established efficacy in a range of
movement disorders, although its exact mode of action
remains unclear. A detailed understanding of mechanism of
DBS would clearly have significant benefits including
refining patient selection and minimising the risk of side
effects. Rather uniquely, the procedure itself may offers
unparalleled opportunities for direct electrophysiological
recordings of brain activity which in turn may allow
insights into the pathophysiology underlying movement
disorders, and also the mechanism by which it has its
effects.
In this month’s journal club, we review three papers
exploring DBS in dystonia. The first paper compares
detailed electrophysiological recordings in patients with
Parkinson’s disease and cervical or limb dystonia,
describing patterns of cortical electrical activity and
observing the effects of DBS. The second paper uses real-
world clinical data to observe globus pallidus neuron firing
rates and patterns, correlating these with clinical outcome
data in paediatric patients with primary or secondary dys-
tonias 1 year post-operatively. Finally the third paper
reports a small series of patients with myoclonus dystonia
undergoing DBS, focussing on symptom improvement,
quality of life, and need for additional pharmacological
treatment at 1 year.
Patterns of cortical synchronisation in isolated
dystonia compared with Parkinson disease
Although DBS is recognised to have an effect in both
Parkinson’s disease (PD) and dystonia, the reasons for its
effect are not clearly understood. The fact that it is effec-
tive in both conditions suggests shared mechanisms. This
paper describes electrophysiological findings in the motor
cortex in dystonia compared to PD, aiming to improve
understanding of underlying pathophysiology. Twenty-two
patients with dystonia (8 limb, 14 cervical), and 14 patients
with akinetic-rigid PD were studied. Intraoperative
recordings were made from the M1 motor strip during rest
and also while performing arm movements, prior to
implantation of the DBS. In all three groups, increased
phase-amplitude coupling was observed, least noticeably in
the cervical dystonia group. The authors report that these
data suggest oversynchronisation of the motor cortex,
which results in impaired initiation and execution of
movement. Furthermore, DBS reduced phase-amplitude
coupling in a subgroup of four dystonia patients studied
both before and during the procedure.
Comment. This study has shed some useful light on the
electrophysiological mechanisms underlying dystonia, and
the extent to which the cortex is involved. The findings
suggest that the therapeutic effect of DBS is to reduce over
synchronisation of the motor cortex, allowing effective
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movement. It would certainly be of value to see these
findings replicated in a larger dataset and to explore whe-
ther similar findings are observed in tremor-dominant PD,
or whether the electrophysiological findings in the cortex
of such patients are different. This would clearly have
important implications on patient selection in maximising
chances of response to DBS.
Miocinovic S et al (2015) JAMA Neurol
72(11):1244–1251.
Differences in globus pallidus neuronal firing rates
and patterns relate to different disease biology
in children with dystonia
This study uses data collected during routine clinical
practice to analyse patterns of firing from globus pallidus
neurons and association of these patterns with outcomes at
1 year following DBS. Children undergoing DBS for
dystonia were included, and classified as either primary
dystonia (with normal imaging) or secondary dystonia.
Secondary dystonia was further subdivided into static
lesions (such as extreme prematurity, vascular event, or
hypoxic ischaemic encephalopathy), and progressive dys-
tonias associated with neurodegenerative conditions such
as PANK-2 deficiency. Data were recorded from the globus
pallidus interna (GPi) and globus pallidus externa (GPe),
and included rate and pattern of firing (burst, regular, or
irregular). Clinical outcomes were defined as improvement
in the movement scale of the Burke–Fahn–Marsden Dys-
tonia Rating Scale (BFMDRS-m).
Firing rates were higher in both GPi and GPe in primary
dystonia and secondary progressive groups compared to
secondary static. For primary and secondary static groups,
most GPi cell firing was non-regular, but in the secondary
progressive group most GPi cells fired in a regular pattern.
There was no difference in firing patterns between groups
for GPe cells.
At baseline, a trend was noted towards association of
lower GPi firing rates with more severe dystonia. At 1 year,
there was significant association between higher GPi firing
rates and percentage improvement in the BFMDRS-m
score. When each group was analysed separately, this
effect was most marked in the secondary static group.
Comment. A strengths of this paper is in its use of real-
world clinical data to analyse electrophysiological findings
and outcome in DBS. The observation of an association
between higher baseline firing rates and outcome at 1 year
is of value, and may be applicable in clinical practice for
counselling patients on expectations for treatment
response. Furthermore these data may offer future oppor-
tunities in establishing markers of prognosis in children
undergoing DBS.
McClelland VM et al (2016) JNNP 2016; E-pub ahead of
print: 4 Feb 2016. doi:10.1136/jnnp-2015-311803
Early deep brain stimulation in patients
with myoclonus-dystonia syndrome
Myoclonus dystonia is a rare movement disorder often with
onset during childhood. In recent years, causative muta-
tions have been identified in the e-sarcoglycan (SGCE)
gene, and there are reports in a small number cases that
have responded to DBS. However, efficacy of DBS
remains unproven in patients negative for SGCE mutations.
This study reports outcome in two patients with myoclonus
dystonia, one with a proven SGCE mutation, and one with
probable myoclonus dystonia by clinical criteria but neg-
ative for known pathogenic mutations. Standard rating
scales were used to score symptoms of myoclonus (Unified
Myoclonus Rating Scale, UMRS) and dystonia (BFMDRS)
pre-operatively and at 6 and 12 months, and the SF-36 was
used to measure quality of life at baseline and 12 months.
The authors also take the opportunity to summarise pre-
vious clinical reports of DBS in myoclonus dystonia.
At 12 months, there was clear improvement in myo-
clonus for both patients of approximately 70 % and for
dystonia of 37 and 86 %. SF-36 scores improved or sta-
bilised. One patient was able to come off medication
altogether, while the other was able to stop one medication
and substantially reduce the dose of a second.
Comment. The limited literature currently available
suggests that DBS is of value for symptom control in
myoclonus dystonia, although may be more effective for
symptoms of myoclonus than dystonia. This case series
supports these observations, and suggests it may also be of
value in gene-negative patients. However, it is important to
note that the aetiology of gene-negative myoclonus dys-
tonia remains unclear, and is likely to differ from disease
due to SGCE mutations, which could have important
implications for treatment. One of the most useful parts of
this paper was the clear summary of previous studies on
DBS in myoclonus dystonia, suggesting that DBS is
effective particularly in patients known to have a mutation
in the SGCE gene. The next step would clearly be a multi-
centre collaboration to investigate long-term outcome in
this rare group of patients.
Rocha H et al (2016) J Clin Neurosci 27:17–21.
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